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Inadequate collateral formation in the heart in diabetic (DM) animals
and patients was considered to be partly caused by a decrease in
vascular endothelial growth factor (VEGF), the key angiogenic factor.
The present study was designed to investigate the therapeutic
implication to improve the defect in VEGF signaling in DM hearts by
ET antagonists. We investigated whether ET-A/B dual receptor antago-
nist (SB209670, 1 mg/kg/day) and ET-A receptor antagonist (TA-0201,
1 mg/kg/day) would reverse the downregulated VEGF signaling in early
streptozotocin (STZ)-induced diabetic hearts with no obvious cardiac
dysfunction in echocardiography. Male Sprague–Dawley rats were
administered citrate saline (vehicle) or STZ (65 mg/kg IP). One week
after the injection, animals were separated into those receiving
SB209670, TA-0201 or vehicle by osmotic mini pump for 2 weeks.
Cardiac ET-1 level was signiﬁcantly increased in DM than in non-DM
rats and SB209670 treatment greatly reversed the higher ET-1 levels in
DM heart than those by the TA-0201 treatment. VEGF level in DM
heart was signiﬁcantly decreased than in non-DM rats, SB209670 and
TA-0201 treatments completely prevented this VEGF downregulation in
DM hearts. The dual ET-A/B receptor blocker was more effective in
reversing the alterations in phosphorylated Akt and eNOS, the two
important downstreams of VEGF angiogenic signaling, in DM heart than
the ETA-receptor antagonist. In conclusion, ET antagonism is effective in
preventing the downregulation of VEGF in diabetic heart, and the dual
ET-A/B receptor antagonist and the selective ETA receptor antagonist
were effective in ameliorating the decreased VEGF signaling and
inadequate coronary collateral development in diabetic hearts.
doi:10.1016/j.lfs.2014.01.022
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Background: Endothelin-1 (ET-1) is implicated in the development
and progression of chronic kidney disease (CKD). It has also been linked
to increased cardiovascular risk in patients with CKD. Here we
evaluated plasma levels of endothelin-like domain peptide (ELDP;
preproET-1[93–166]) and CT-proET-1 (preproET-1[169–212]) in pa-
tients with proteinuric CKD after treatmentwith sitaxentan. Changes in
proET-1 peptides were compared with various parameters of cardio-
vascular and renal function. Methods and results: Twenty-seven
patients with proteinuric CKD receiving recommended renoprotective
treatment were randomised to 6 weeks of placebo, sitaxentan (100 mg
once daily), and nifedipine long-acting (30 mg once daily), in a double-
blind, three-way crossover study design. Renal and cardiovascular
function, and plasma biomarkers were measured at baseline, week 3,
and week 6 of each treatment period. ELDP and CT-proET-1 were
measured by speciﬁc sandwich ELISAs. Sitaxentan treatment resulted in
signiﬁcant increases in ELDP and CT-proET-1 at both 3 and 6 weeks
compared to baseline (mean increases % ± sem at 3 and 6 weeks:
ELDP +17.5 ± 3.2, +15.0 ± 3.5; CT-proET-1 + 12.9 ± 2.0, +14.4
± 2.6; p b 0.001 for all values). Placebo and nifedipine had no effect
on plasma ELDP and CT-proET-1. After 6 weeks sitaxentan plasma ELDP
and CT-proET-1 were negatively correlated with 24 h urinary Na+
excretion (p= 0.015, r2 = 0.2149; p = 0.013, r2 = 0.2227, respec-
tively). Conclusions: Increases in proET-1 biomarkers after sitaxentan
indicate that ETA antagonists block a negative feedback effect of ET-1 on
EDN1 gene expression that is mediated via ETA receptors. The inverse
relationship between plasma proET-1 biomarkers and urinary Na+
excretion after sitaxentan requires further investigation.
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Aging is a main risk factor for carotid artery disease and stroke.
The constrictor peptides endothelin-1 and angiotensin II are
important modiﬁers of age-induced vascular diseases, partly through
altered activity of NADPH oxidase (Nox)-derived superoxide and
constrictor prostanoids. Whether aging affects Nox- or prostanoid-
mediated constrictor responses to endothelin-1 or angiotensin II in
carotid arteries is unknown. We studied contractions to endothelin-1
(0.1–100 nmol/L) and angiotensin II (100 nmol/L) in isolated com-
mon carotid artery rings from young and old C57BL6 mice (4 and
24 months of age). The nitric oxide synthase inhibitor l-NAME
(300 μmol/L) was used throughout the study to exclude endothelin
ETB receptor- or angiotensin AT2 receptor-mediatednitric oxide release
during contractions, which are given relative to KCl (60 mmol/L)-
induced responses. Some arteries were additionally incubated with the
Nox- speciﬁc inhibitor gp91ds-tat (3 μmol/L) or the thromboxane-
prostanoid receptor antagonist SQ 29′548 (1 μmol/L) for 30 min. Aging
markedly reducedmaximal responses (Emax) and the sensitivity (pD2)
to endothelin-1 (Emax 8.9 ± 1.8% vs. 26.2 ± 3.8%, 3-fold, P b 0.001;
pD28.02 ± 0.07 vs. 8.54 ± 0.02, P b 0.01). Inhibition of Nox activity
blunted endothelin-1-induced contractions by 42% and 63% in young
and old animals, respectively (P b 0.05), while the thromboxane-
prostanoid receptor antagonist had no effect in either group. Contrac-
tions to angiotensin II were weak in young and old animals (3.6 ± 0.4%
vs. 3.1 ± 0.2%, P = n.s.) and unaffected by gp91ds-tat or SQ 29′548. In
summary, aging selectively impairs contractions to endothelin-1 in
carotid arteries, which depend on Nox activity, but not on constrictor
prostanoids. Endothelin-1 but not angiotensin II seems to be involved in
functional aging of carotid arteries.
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